Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor.

Tsai, Alice; Wu, Shu-Pei; Haseltine, Eric; Kumar, Sanjeev; Moskowitz, Samuel M; Panorchan, Paul; Shah, Kushal

Tsai, Alice; Wu, Shu-Pei; Haseltine, Eric; Kumar, Sanjeev; Moskowitz, Samuel M; Panorchan, Paul; Shah, Kushal.

Afiliación

Tsai A; Vertex Pharmaceuticals Incorporated, Boston, MA, USA. alice_tsai@vrtx.com.
Wu SP; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Haseltine E; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Kumar S; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Moskowitz SM; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Panorchan P; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Shah K; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.

Pulm Ther ; 6(2): 287, 2020 Dec.

Article en En | MEDLINE | ID: mdl-32856286

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Pulm Ther Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Pulm Ther Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos